Citi initiated coverage of the stock with a Buy rating and a target price of $20 per share, implying a premium of about 60% over the last close. ・The company has rightly positioned itself to address ...

Artificial intelligence has long been seen as a way to supercharge drug development. But a whole new frontier of computing is opening up at cutting-edge labs around the globe—and Big Pharmas are ...